ClinicalTrials.Veeva

Menu

Urinary and Prostate Microbiotes and Prostate Cancer (MICROPROSTK)

C

Centre Hospitalier Universitaire de Nice

Status

Completed

Conditions

Prostatic Neoplasm

Treatments

Other: Urinary sampling
Procedure: prostate biopsy
Other: Rectal swabbing before biopsies are performed

Study type

Interventional

Funder types

Other

Identifiers

NCT03947515
18-API-02

Details and patient eligibility

About

In recent decades, the cancer process has been linked to microbial infections, particularly in gastric and Helicobacter pylori cancers, but also in cervical cancers promoted by exposure to Human papilloma virus (HPV). More recently, it has been shown that bacteria in the intestinal microbiota could promote the development of colorectal cancer by modulating the inflammatory response within the intestinal mucosa. Among male cancers, prostate cancer is the leading cause in France with 54,000 new cases per year. In addition, the dogma that urine is sterile has been broken and the notion of the presence of a "urinary microbiota" in asymptomatic patients is now accepted.

While the risk factors associated with this cancer have not yet been clearly elucidated, recent evidence in the literature agrees that chronic inflammation associated with prostate infection plays a key role as a factor that may promote the development and/or progression of prostate cancer. Most recently, a study shows for the first time that a group of 6 bacteria is found significantly higher in the urine of patients with prostate cancer than in patients with prostate adenoma. Interestingly, clinical microbiology studies conducted at the bacteriology laboratory of the University Hospital of Nice on A. schaalii have shown that this species is also isolated in the urine of patients with bladder and prostate cancers.

The investigators wish to study the association of the 6 bacterial species mentioned above with prostate cancer by directly analyzing the prostate tissue of patients with this condition.

the staff will carry out a multicenter case-control study by recruiting a total of 260 patients in 4 centres (Nice coordinating centre, Marseille, Tours and Nîmes): 130 in the prostate cancer group and 130 in the prostate adenoma control group. This project is a research involving the human person of category 2.

The innovative aspect of the work consists in detecting and quantifying in situ in the prostate tissue the presence of these 6 bacterial species per culture and per PCR in real time, comparing the prostate microbiota in terms of richness and diversity between cancer patients and those without cancer. Ultimately, this study opens up exciting prospects with the possibility of determining a microbial origin of prostate cancer and considering antibiotic therapy for anti-cancer purposes such as H. pylori and gastric cancer.

Enrollment

296 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • over 18 years old
  • Male sex
  • Patient with a prostate biopsy programmed for suspected prostate adenocarcinoma on elevation of PSA and/or TR suspect and/or MRI suspect
  • Signed Informed Consent
  • Affiliation to a social security system

Exclusion criteria

  • Taking systemic antibiotic treatment (per os or I.V.) within 3 months before inclusion.
  • Contraindications to the performance of an ultrasound-guided transrectal prostate biopsy: coagulation disorders and urogenital infections.
  • History of surgical treatment of the urinary and genital tract within 6 months before inclusion
  • Person under guardianship, curatorship or unable to express consent.

Trial design

Primary purpose

Basic Science

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

296 participants in 2 patient groups

cancer group
Experimental group
Treatment:
Other: Urinary sampling
Procedure: prostate biopsy
Other: Rectal swabbing before biopsies are performed
control group
Experimental group
Treatment:
Other: Urinary sampling
Procedure: prostate biopsy
Other: Rectal swabbing before biopsies are performed

Trial contacts and locations

4

Loading...

Central trial contact

romain LOTTE

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems